Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZYN002 for symptoms of Fragile X syndrome in children and adolescents
ACTRN12618001063202Phase 2Completed
- Sponsor
- Zynerba Pharmaceuticals
- Start
- Jun 2018
- Modality
- Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 3
01
Overview
A Phase 2 trial of Zygel in Fragile X syndrome (FXS), sponsored by Zynerba Pharmaceuticals. Started Jun 2018; status: completed.
02
Drugs
Zygel
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on ACTRN12618001063202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001063202.